Publicaciones
El conocimiento generado en IrsiCaixa se comparte con la comunidad científica a través de la publicación de artículos en revistas científicas de alto impacto.
Effect of milk thistle on the pharmacokinetics of darunavir-ritonavir in HIV-infected patients.
Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers.
Herb-drug interaction between Echinacea purpurea and etravirine in HIV-infected patients.
Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients.
Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients.
Minimal removal of raltegravir by hemodialysis in HIV-infected patients with end-stage renal disease.
Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.
Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.
Efficacy and safety of ritonavir dose reduction based on the tipranavir inhibitory quotient in HIV-infected patients on salvage antiretroviral therapy with tipranavir/ritonavir.
Saquinavir exposure in HIV-infected patients with chronic viral hepatitis.